{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T18:42:01Z","timestamp":1771353721111,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>In the early stages of treating patients with SARS-CoV-2, limited information was available to guide antimicrobial stewardship interventions. The COVID-19 Task Force and Antimicrobial Stewardship Committee, at a 988-bed academic medical center, implemented the use of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab polymerase chain reaction (PCR) testing to assist with the de-escalation of anti-MRSA therapy in patients with suspected superimposed bacterial pneumonia in COVID-19. A retrospective study was conducted to evaluate the impact of MRSA nasal swab PCR testing on the rate of anti-MRSA therapy between 13 April 2020 and 26 July 2020. A total of 122 patients were included in the analysis. Of the patients included in the final analysis, 58 (47.5%) had anti-MRSA therapy discontinued and 41 (33.6%) avoided anti-MRSA therapy completely due to a negative swab result. With the implementation of MRSA nasal swab PCR testing in COVID-19 patients, anti-MRSA therapy was reduced in 81% of patients in this study. In patients who continued with anti-MRSA therapy, nasal swabs were either positive for MRSA or an alternative indication for anti-MRSA therapy was noted. Only three patients in the cohort had MRSA identified in a sputum culture, all of whom had anti-MRSA therapy continued. MRSA nasal swab PCR testing may serve as an effective antimicrobial stewardship tool in COVID-19 pneumonia.<\/jats:p>","DOI":"10.3390\/antibiotics12020253","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T01:58:59Z","timestamp":1674784739000},"page":"253","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Implementation of MRSA Nasal Swabs as an Antimicrobial Stewardship Intervention to Decrease Anti-MRSA Therapy in COVID-19 Infection"],"prefix":"10.3390","volume":"12","author":[{"given":"Alaina","family":"DeKerlegand","sequence":"first","affiliation":[{"name":"Pharmacy Department, Methodist University Hospital, Memphis, TN 38104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Johnston","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA 70808, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britney","family":"Mellor","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA 70808, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie Rae","family":"Schrack","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA 70808, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"O\u2019Neal","sequence":"additional","affiliation":[{"name":"Medical Staff Office, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA 70808, USA"},{"name":"Louisiana State University Health Sciences Center, Baton Rouge, LA 70808, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/irv.12398","article-title":"The frequency of influenza and bacterial coinfection: A systematic review and meta-analysis","volume":"10","author":"Klein","year":"2016","journal-title":"Influ. Other Respir. Viruses"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3389\/fmicb.2017.01041","article-title":"Secondary Bacterial Infections Associated with Influenza Pandemics","volume":"8","author":"Morris","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the american thoracic society and infectious diseases society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","first-page":"2459","article-title":"Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing","volume":"71","author":"Rawson","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2020.05.046","article-title":"Co-infections in people with COVID-19: A systematic review and meta-analysis","volume":"81","author":"Lansbury","year":"2020","journal-title":"J. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bhimraj, A., Morgan, R.L., Shumaker, A.H., Lavergne, V., Baden, L., Cheng, V.C.-C., Edwards, K.M., Gandhi, R., Muller, W.J., and O\u2019Horo, J.C. (2020). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with (COVID-19). Clin. Infect. Dis., ciaa478. v1.0.4.","DOI":"10.1093\/cid\/ciaa478"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.7812\/TPP\/14-101","article-title":"Nasal Methicillin-Resistant Staphylococcus aureus Polymerase Chain Reaction: A Potential Use in Guiding Antibiotic Therapy for Pneumonia","volume":"19","author":"Johnson","year":"2015","journal-title":"Perm. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.diagmicrobio.2016.08.011","article-title":"Clinical utility of a nasal swab methicillin-resistant Staphylococcus aureus polymerase chain reaction test in intensive and intermediate care unit patients with pneumonia","volume":"86","author":"Giancola","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jcrc.2016.11.008","article-title":"Clinical utility of methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction assay in critically ill patients with nosocomial pneumonia","volume":"38","author":"Smith","year":"2017","journal-title":"J. Crit. Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy024","article-title":"The Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial Stewardship Implications","volume":"67","author":"Parente","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/phar.2188","article-title":"Clinical Utility of Methicillin-Resistant Staphylococcus aureus Nasal Screening for Antimicrobial Stewardship: A Review of Current Literature","volume":"38","author":"Carr","year":"2018","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/cid\/ciz974","article-title":"Determining the Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening in Antimicrobial Stewardship","volume":"71","author":"Mergenhagen","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1093\/cid\/ciaa1239","article-title":"Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study","volume":"72","author":"Vaughn","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cmi.2020.07.041","article-title":"Incidence of co-infections and superinfections in hospitalized patients with COVID-19: A retrospective cohort study","volume":"27","author":"Sanjuan","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Alshaikh, F.S., Godman, B., Sindi, O.N., Seaton, R.A., and Kurdi, A. (2022). Prevalence of bacterial coinfection and patterns of antibiotics prescribing in patients with COVID-19: A systematic review and meta-analysis. PLoS ONE, 17.","DOI":"10.1101\/2022.03.02.22271779"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bhimraj, A., Morgan, R.L., Shumaker, A.H., Baden, L., Cheng, V.C.C., Edwards, K.M., Gallagher, J.C., Gandhi, R.T., Muller, W.J., and Nakamura, M.M. (2022). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin. Infect. Dis., ciac724. v10.0.0.","DOI":"10.1093\/cid\/ciac724"},{"key":"ref_18","unstructured":"(2022). COVID-19: U.S. Impact on Antimicrobial Resistance, U.S. Department of Health and Human Services, CDC. Special Report 2022."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.cmi.2020.12.018","article-title":"Antibiotic prescribing in patients with COVID-19: Rapid review and meta-analysis","volume":"27","author":"Langford","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2020.1291","article-title":"Changes in antimicrobial utilization during the coronavirus disease 2019 (COVID-19) pandemic after implementation of a multispecialty clinical guidance team","volume":"42","author":"Staub","year":"2021","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/jmv.25884","article-title":"Clinical Characteristics of 3,062 COVID-19 Patients: A Meta-Analysis","volume":"92","author":"Zhu","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e799","DOI":"10.1097\/CCM.0000000000004457","article-title":"ICU and ventilator mortality among critically ill adults with COVID-19","volume":"48","author":"Auld","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.kint.2020.03.005","article-title":"Kidney impairment is associated with in-hospital death of COVID-19 patients","volume":"97","author":"Cheng","year":"2020","journal-title":"Kidney Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1681\/ASN.2020040419","article-title":"Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology","volume":"31","author":"Batlle","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Fabrizi, F., Alfieri, C.M., Cerutti, R., Lunghi, G., and Messa, P. (2020). COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis. Pathogens, 9.","DOI":"10.3390\/pathogens9121052"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"Paterson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.2215\/CJN.05920616","article-title":"Vancomycin and the risk of AKI: A systematic review and meta-analysis","volume":"11","author":"Haikal","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/jcpt.12762","article-title":"Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study","volume":"44","author":"Kim","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/jcpt.13143","article-title":"Linezolid and fentanyl: An underrecognized drug-to-drug interaction","volume":"45","author":"Campioli","year":"2020","journal-title":"J. Clin. Pharm. Ther."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/2\/253\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:16:40Z","timestamp":1760120200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/2\/253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["antibiotics12020253"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12020253","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}